ArticleWorld journal of surgical oncology2023

PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China.

Xiaoyu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.